Ardelyx reported its first quarter 2025 financial results on May 1, 2025, with total revenue reaching $74.1 million, a 61% increase year-over-year. IBSRELA net product sales revenue was $44.4 million, reflecting approximately 57% year-over-year growth driven by increased demand indicators.
XPHOZAH net product sales revenue for the quarter was $23.4 million. This figure includes a $3.8 million release of prior periods’ estimated product returns, and excluding this, net sales revenue grew 30% compared to Q1 2024. The company also recognized $5.0 million in licensing revenue from Fosun Pharma following tenapanor's approval in China.
Despite strong revenue growth, Ardelyx reported a net loss of $41.1 million, or $(0.17) per share, a significant widening from previous periods. The company reaffirmed its full-year 2025 IBSRELA net sales guidance of $240.0 million to $250.0 million and ended the quarter with $214.0 million in cash, cash equivalents, and investments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.